Videos

RSS icon
Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy. 
 

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

William P. Shutze, MD, FACS, secretary of the Society of Vascular Surgery (SVS), a vascular surgeon with Texas Vascular Associates in Plano, Texas, and a clinical associate professor of medicine at Texas A&M College of Medicine, explained the role of vascular surgeons in peripheral artery disease (PAD) and critical limb ischemia (CLI).

Getting vascular surgeons more involved leads to key improvements for PAD patients

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

Radiologist Michael Morris, MD, radiologist and director of cardiac CT and MRI at Banner Health, explains how cardiac radiology imaging is moving toward expanded use of fractional flow reserve CT (FFR-CT) and artificial intelligence analysis of coronary CT angiography (CCTA) exams as a standard of care. He spoke to Radiology Business during RSNA 2025.

Radiology embraces FFR-CT and AI plaque analysis as cardiac imaging evolves

The specialty is moving toward expanded use of fractional flow reserve CT and AI analysis of coronary CT angiography exams as a standard of care.

Workflow efficiencies and automation enhance newer cardiovascular IT systems

9 ways cardiovascular IT systems can improve your day-to-day workflow

Bringing in a new and improved cardiovascular IT system can save physicians a ton of time and lead to considerable cost savings.

Video interview with Anders Gilberg, MGA, senior vice president, government affairs at Medical Group Management Association (MGMA), explains various value-based payment models the Centers for Medicare and Medicaid Services (CMS) is experimenting with, but notes out or more than 30 models, only two have actually saved Medicare money.

MGMA outlines path and pitfalls in CMS 2030 value-based care push

The Center for Medicare and Medicaid Innovation (CMMI) has tested nearly 40 APMs, of which only two turned out to be successful, which does not bode well for meeting a 2030 deadline to transition to value-based payments.
 

Displaying 97 - 104 of 751
Design by Adaptive Theme